Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Translational Genomics Research Institute (TGEN) currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The institute's prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. COOK, LISA V is the busiest examiner, overseeing 1 busiest examiner pending action. This concentration in 1 distinct art unit suggests a specialized genomic focus for the institute's current filings.
Because there is 1 pending office action, the institute's current prosecution strategy is focused on a point of contact at the USPTO, making the resolution of this case the task for its pharmaceutical patent efforts. This allows the practitioner to tailor arguments specifically to the preferences and history of COOK, LISA V. The focus on 1 distinct examiner means that the institute can concentrate its resources on a set of legal and technical arguments. This can be more efficient than managing multiple pending actions across different art units with varying standards of review.
The 1 busiest examiner pending action represents the entirety of the institute's current active prosecution. This makes the upcoming response to the 1 pending office action a priority task for the institute's intellectual property strategy. A successful outcome in this case would establish a foundation for the institute's Biotechnology & Pharmaceuticals portfolio. The narrow administrative footprint of the portfolio allows for a precise approach to the patent office, focusing on the specific requirements of the assigned art unit and the 1 distinct examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COOK, LISA V | 1 | 67.6% | +9.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921275 | BIOMARKERS FOR DETECTION OF LUNG CANCER | COOK, LISA V | 147d overdue |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921275 | BIOMARKERS FOR DETECTION OF LUNG CANCER | COOK, LISA V | 1642 | §101§103§112Other | Final Rejection | 147d overdue | Pending | Oct 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial